Antiplatelet agents and anticoagulants for hypertension

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Elevated blood pressure (hypertension) is linked to thrombotic complications like coronary heart disease (CHD), ischemic strokes, and peripheral vascular disease (PVD).
• Hypertension-related conditions such as heart failure and atrial fibrillation also increase stroke and thromboembolic risk.
• Investigating antithrombotic therapy is crucial for preventing thrombosis-related issues in hypertensive individuals.

Purpose of the Study:

• To systematically review the efficacy of antiplatelet therapy and anticoagulation in patients with high blood pressure.
• To assess if antiplatelet agents reduce mortality and major thrombotic events versus placebo or other treatments.
• To determine if oral anticoagulants reduce mortality and major thromboembolic events versus placebo or other treatments.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) in patients with elevated blood pressure, lasting at least 3 months.
• Searched major electronic databases (MEDLINE, EMBASE, etc.) and conference abstracts up to January 2011.
• Independent data collection and verification by two reviewers, with data pooling where appropriate.

Main Results:

• Acetylsalicylic acid (ASA) did not reduce stroke or all cardiovascular events in primary prevention for hypertension without prior cardiovascular disease.
• In one trial, ASA reduced myocardial infarction but increased major hemorrhage risk over 5 years.
• Antiplatelet therapy demonstrated significant benefit for secondary prevention in patients with elevated blood pressure, with a 4.1% absolute reduction in vascular events.

Conclusions:

• For primary prevention in hypertension, ASA's benefit (myocardial infarction reduction) is negated by similar harm (major hemorrhage).
• Antiplatelet therapy offers substantial benefits for secondary prevention in hypertensive patients, greatly outweighing the harms.
• Warfarin therapy has not shown benefit, and newer agents require further evaluation in high blood pressure populations.